Jingwu Zhang Zang
Director/Board Member bei HH&L ACQUISITION CO.
Vermögen: 8 Mio $ am 31.03.2024
Profil
Jing Wu Zang, Gründer von I-Mab und I-Mab Biopharma (Shanghai) Co., Ltd. ist Chairman bei I-Mab und Chairman & Chief Executive Officer von I-Mab Biopharma (Shanghai) Co., Ltd. (eine Tochtergesellschaft von I-Mab). Dr. Zang ist auch im Vorstand von HH&L Acquisition Co. In seiner früheren Laufbahn war Dr. Zang President & Chief Scientific Officer bei Simcere Pharmaceutical Group Ltd, President & Chief Scientific Officer bei BioSciKin Co., Ltd, Director-Shanghai Institute of Immunology an der Shanghai Jiaotong University School of Medicine, Senior VP, Head-Research & Development bei Glaxosmithkline China Ltd, Principal bei Opexa Pharmaceuticals, Inc. und Professor am Baylor College of Medicine. Jing Wu Zang erhielt einen Doktortitel von der Shanghai Jiao Tong University und einen Doktortitel von der Vrije Universiteit Brussel.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
I-MAB
4,98% | 31.12.2023 | 9 449 021 ( 4,98% ) | 8 Mio $ | 31.03.2024 |
Aktive Positionen von Jingwu Zhang Zang
| Unternehmen | Position | Beginn |
|---|---|---|
| HH&L ACQUISITION CO. | Director/Board Member | 04.02.2021 |
I-MAB Biopharma Co., Ltd.
 I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Founder | 01.06.2016 |
Ehemalige bekannte Positionen von Jingwu Zhang Zang
| Unternehmen | Position | Ende |
|---|---|---|
| I-MAB | Chief Executive Officer | 30.09.2022 |
| SIMCERE PHARMACEUTICAL GROUP LIMITED | President | 01.04.2016 |
BioSciKin Co., Ltd.
 BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | President | 01.04.2016 |
| Glaxosmithkline China Ltd. | Chief Tech/Sci/R&D Officer | 01.06.2013 |
| Shanghai Jiao Tong University School of Medicine | Corporate Officer/Principal | 01.04.2007 |
Ausbildung von Jingwu Zhang Zang
| Shanghai Jiao Tong University | Doctorate Degree |
| Vrije Universiteit Brussel | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SIMCERE PHARMACEUTICAL GROUP LIMITED | Health Technology |
| I-MAB | Health Technology |
| Private Unternehmen | 7 |
|---|---|
| Opexa Pharmaceuticals, Inc. | Health Technology |
Institut Pasteur de Shanghai
 Institut Pasteur de Shanghai Miscellaneous Commercial ServicesCommercial Services Institut Pasteur de Shanghai operates as a non-profit life sciences organization. The private company is based in Shanghai, China. | Commercial Services |
| Glaxosmithkline China Ltd. | |
| The Institute of Health Sciences | |
BioSciKin Co., Ltd.
BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | Health Technology |
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Health Technology |
HH&L Acquisition Co.
 HH&L Acquisition Co. Financial ConglomeratesFinance HH&L Acquisition Co. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on September 4, 2020 and is headquartered in Hong Kong. | Finance |
